Targeted Legumain-Cleavable Top1i ADC Platform
This technology introduces a legumain-cleavable antibody drug complex that delivers a topoisomerase inhibitor directly into tumor cells. Its short, polar linker design enables controlled intracellular release, improving targeting precision and therapeutic potential. In contrast to other related technologies, this invention employs low-potency Top1i...
Published: 4/28/2026
|
Inventor(s): Lawrence Tumey, Nicholas Bianchi, Victor Ojo
Keywords(s): Technologies
Category(s): Campus > Binghamton University, Technology Classifications > Antibodies, Technology Classifications > Therapeutics and Vaccines
|